Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label basket study of vibostolimab coformulated with pembrolizumab in selected advanced solid tumors
MOH_2021-08-20_010216Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vibostolimab and pembrolizumab in Cervical Cancer (CC), endometrial cancer (EC), head and neck squamous cell carcinoma (HNSCC) and 5 more (10 arms), sponsored by Merck & Co. Primary endpoints: Safety of MK-7684A alone or in combination, Antitumor activity in cervical cancer versus pembrolizumab and 1 more. Started Jul 2021; status: completed.
02
Drugs
vibostolimabpembrolizumab
03
Conditions
Cervical Cancer (CC)endometrial cancer (EC)head and neck squamous cell carcinoma (HNSCC)biliary canceresophageal cancer
Beyond the preview
Go deeper on MOH_2021-08-20_010216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-20_010216.